The future of genome editing is in vivo! Check out our latest PNASNews perspective from Doudna Lab. Had a lot of fun discussions with Kevin Wasko and Jennifer R Hamilton about the past, present, and future of in vivo delivery.

pnas.org/doi/10.1073/pn…

How genome editing can be more efficacious and accessible in the future.
Delivery of editors without virus vectors.
pnas.org/doi/10.1073/pn…
PNASNews Doudna Lab Connor Tsuchida UC Berkeley

The Hachiman defense system functions through sensing genome integrity. Beautiful structure function study by the Doudna Lab. Congrats Owen Tuck Ben Adler et al!
biorxiv.org/content/10.110…

A beautiful story by two terrific scientists!! Finally Hachiman has a mechanism!!

Congrats Owen and Ben on this great work!

Mechanism of the Hachiman immune system finally deciphered

A beautiful study from the Doudna lab shows that Hachiman is a genome integrity sensor

biorxiv.org/content/10.110…

Congrats Doudna Lab and colleagues!

Hachiman is hot off the (preprint) presses! Owen Tuck and I in Doudna Lab present a model for how this broad-activity defense system recognizes genome integrity, a core feature of phage infection.

Check out the preprint and Owen's thread for the news:

New preprint on phage defense from the lab co-led by Owen Tuck and Ben Adler - check it out!

The first paper of this year, “Engineering self-deliverable ribonucleoproteins for genome editing in the brain”, is officially out Nature Communications. This is the first project of my postdoc Doudna Lab, where we focused on delivery method development for CRISPR genome editors in the…

Very happy to share my first postdoc paper! We predicted the structures of 67,715 viral proteins to study their evolution and function. In addition to lots of cool findings, I hope this structural resource is helpful to the community! biorxiv.org/content/10.110…

In vivo human T cell engineering with enveloped delivery vehicles go.nature.com/47vW1Rp

The Danaher Corporation Innovative Genomics Institute UC Berkeley MCB Beacon for CRISPR Cures aims to solve an 'unsolvable' challenge: how to develop such cures for 'rare' diseases that, at present, have low to zero commercial value.
statnews.com/2024/01/09/dou…
As Jason Mast STAT explains, doing so will…

Only in the University of California system can we leverage clinical expertise UC San Francisco w/ CRISPR editing UC Berkeley & cell manufacture UCLA to partner with Danaher Corporation to advance therapies for patients with rare diseases
Doudna Lab Fyodor Urnov The Kohn Lab UCLA Innovative Genomics Institute
ucsf.edu/news/2024/01/4…

Grateful to be part of this team of 'superheroes' partnering with Danaher Corporation to bring CRISPR to bear on the space of rare diseases, starting with Artemis-deficient SCID and HLH, and eventually other inborn errors of immunity! Where would the Avengers be without SHIELD?

IGI is teaming up with Danaher Corporation to focus on creating treatments for two rare immune disorders! We hope to scale this work into a #CRISPR platform in which a new medicine for any genetic disease can be rapidly developed. Learn more: ow.ly/aElX50Qp2qn

#RareDisease

Excited to lead the Artemis-SCID project team for the new Innovative Genomics Institute Danaher Corporation collaboration to advance CRISPR therapies for rare diseases UCSF Benioff SF!
Doudna Lab Fyodor Urnov The Kohn Lab UCLA @ucsf UCSF Pediatrics

Here's the non-paywall IGI press release